52North develops in-vitro diagnostic and digital solutions aimed at improving the safety and effectiveness of emergency care. Their product portfolio includes Neutrocheck®, a portable blood test for identifying neutropenic sepsis risk, and ACORN™, a digital tool for remote triage in emergency cancer care. The company leverages its Aster™ platform for rapid, multiplexed cell measurement from single samples.

Adendra Therapeutics develops dendritic cell‑focused immunotherapies for solid tumors and autoimmune diseases. By engineering vectors that deliver tumor‑specific or autoantigen peptides together with proprietary adjuvant blends, the platform enhances antigen presentation and steers immune responses for either tumor eradication or immune tolerance. The modular, GMP‑compatible system enables rapid creation of personalized vaccine candidates and combination‑ready formats for pharmaceutical partners.

Aethon Therapeutics uses its HapImmune™ platform to engineer antibodies that create synthetic neoantigens on drug‑resistant cancer cells after exposure to targeted therapies, such as KRAS‑G12C inhibitors. These hapten‑peptide constructs flag the resistant cells for immune clearance, enabling selective antibody‑mediated killing while sparing normal tissue. The modular system is designed for partnership with pharmaceutical and biotech companies to enhance the durability of targeted oncology treatments.

AiM Medical Robotics is developing a robotic system that employs precision robotic manipulation and advanced imaging technologies for neurosurgical procedures. This system enhances surgical accuracy and minimizes complications during complex brain surgeries.

Akamis Bio develops T‑SIGn® therapeutics, systemically administered virus‑based oncolytic immunotherapies that selectively replicate in colorectal tumor cells and deliver immune‑modulating payloads directly to the tumor microenvironment. By combining direct oncolysis with intratumoral production of antibodies, cytokines or bispecific proteins, these agents aim to enhance antitumor immunity and reduce the need for invasive surgery in locally advanced and metastatic colorectal cancer.

Alia Therapeutics is developing next-generation gene-editing therapies that utilize precise genome editing techniques to target and correct mutations responsible for rare genetic diseases. By focusing on the efficacy and durability of these treatments, the company aims to provide long-lasting cures that address the root causes of genetic disorders.

Api operates self-service grocery stores in rural areas, providing 700 essential products at supermarket prices, accessible 24/7 through a mobile app that generates a unique QR code for entry. This model addresses the lack of local commerce in villages, enabling residents to shop conveniently without the need for long-distance travel to larger stores.

Arda Therapeutics develops therapies aimed at eliminating pathogenic cells that drive chronic diseases. The company utilizes single-cell data analysis to precisely identify and characterize these target cells. This approach informs the design of specific therapies engineered to selectively eliminate only the disease-driving cell populations.

The startup develops targeted cancer therapies that exploit DNA damage response pathways to induce synthetic lethality in cancer cells. By focusing on specific mutations, their treatments aim to enhance the selective destruction of malignant cells while minimizing harm to healthy tissue.

BioCaptiva develops msX™, a proprietary polymer technology that captures circulating free DNA (cfDNA) directly from biological fluids without additional reagents, enhancing sample yield and stability. This technology addresses the limitations of current liquid biopsy methods, enabling non-invasive cancer diagnosis and monitoring with improved sample quality and reduced risk of failure.

BliNK Biomedical provides a B‑cell technology platform that directly screens and isolates individual antibody‑producing cells from human and other animal sources, using its proprietary ISAAC and VIVA|Screen systems. The high‑throughput, deep‑mining approach can detect extremely rare antibody‑secreting cells across multiple species, enabling the generation of unique therapeutic antibody candidates that are difficult to obtain with conventional methods.

Cyted utilizes artificial intelligence and digital pathology to enhance the detection of upper gastrointestinal diseases, including pre-cancerous conditions. Their non-endoscopic diagnostic platform, EndoSign®, enables earlier diagnosis and improved access to care for millions affected by these conditions globally.

ViewFinder utilizes advanced machine learning algorithms to enhance the interpretation of 3D X-ray images for breast cancer diagnosis. The platform provides radiologists with improved accuracy and efficiency in identifying potential malignancies, ensuring timely and effective patient care.

Enedra Therapeutics develops precision medicines that leverage synthetic lethality and computational systems biology to target the genetic heterogeneity of tumors. This approach addresses the challenge of poor survival rates in cancer patients by creating personalized therapies tailored to specific tumor profiles.

Infinitopes develops a precision immunomics platform that identifies highly-expressed tumor antigens and employs advanced vector delivery systems to enhance T cell immunity against cancer. By initiating vaccine treatment at early stages of the patient's journey, the company aims to improve patient outcomes and reduce the risk of metastases.

iOnctura develops precision oral small molecules targeting neglected and hard-to-treat cancers by modulating key signaling pathways, including allosteric modulation of PI3Kδ and inhibition of autotaxin. Their therapies aim to reduce the severe side effects associated with conventional treatments, thereby improving patient healthspan and overall survival.

Laigo Bio develops SureTACs, bispecific antibodies that facilitate the targeted degradation of membrane proteins linked to tumors and neurological diseases by promoting their ubiquitination and subsequent lysosomal removal. This technology addresses the challenge of treating previously undruggable targets, enhancing therapeutic specificity and efficacy in oncology and beyond.

Mos provides a financial platform for students that combines scholarship matching from a $160 billion database with personalized financial aid advisory services. This solution addresses the challenge of securing funding for education by simplifying the scholarship application process and enhancing access to financial resources.

Myricx Bio develops novel payloads for antibody-drug conjugates (ADCs) that inhibit N-myristoyltransferases (NMT) to target cancer cells. Their proprietary ADCs demonstrate significant preclinical efficacy and safety against various solid tumor-associated antigens, addressing the need for effective cancer treatments.

NK:IO develops novel NK cell and small molecule therapies to overcome limitations in current cancer immunotherapy approaches. The company utilizes proprietary platform technologies to enhance NK cell expansion and tumor-killing capacity for treating solid and hematological tumors. Their focus is on creating highly functional NK cell therapeutics that avoid the exhaustion phenotype seen in competing technologies.

Om provides access to massive, internally generated datasets detailing proteome-wide small molecule binding data. Researchers can programmatically query billions of protein and small molecule interaction data points to identify therapeutic opportunities instantly. The platform leverages synthetic biology and pico-scale engineering to accelerate the transition from hypothesis to launching a discovery program.

Revitope Oncology is developing a novel class of bispecific antibody therapeutics utilizing its proprietary TwoGATE™ technology, which employs dual antigen targeting to activate T cells exclusively on tumor cells. This approach addresses the challenge of "on-target, off-tumor" toxicity in traditional immunotherapies by ensuring that immune activation occurs only when both targeted antigens are present, thereby enhancing safety and efficacy in treating solid tumors.

Sentinal4D uses AI to analyze tumor cells at a single-cell level, providing personalized diagnoses for cancer patients. This enables the development of targeted cancer therapies based on individual tumor characteristics.

SION is a commission management software tailored for travel agents that automates commission tracking and reporting to improve financial workflows. The platform eliminates the inefficiencies of manual commission reconciliation and payment processing, enabling agents to enhance profitability and operational efficiency.